A detailed history of Axq Capital, LP transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 49,677 shares of TSHA stock, worth $209,140. This represents 0.06% of its overall portfolio holdings.

Number of Shares
49,677
Previous 57,000 12.85%
Holding current value
$209,140
Previous $132 Million 23.37%
% of portfolio
0.06%
Previous 0.04%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 10, 2025

SELL
$2.34 - $3.29 $17,135 - $24,092
-7,323 Reduced 12.85%
49,677 $162 Million
Q2 2025

Aug 12, 2025

BUY
$1.13 - $2.9 $64,409 - $165,300
57,000 New
57,000 $132 Million
Q4 2024

Feb 11, 2025

BUY
$1.27 - $3.24 $28,488 - $72,679
22,432 New
22,432 $38.8 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $204M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Axq Capital, LP Portfolio

Follow Axq Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Axq Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Axq Capital, LP with notifications on news.